Artificial Intelligence for Chronic Kidney Disease (CKD)
Dr. Steven Coca discusses the product of RenalytixAI called KidneyIntelX, a diagnostic solution that uses artificial intelligence to assess the combination of predictive blood-based biomarkers and other genomic information, in combination with electronic health record information, to create a powerful model for the prediction of disease progression and drug/therapy response in individual patients at risk for CKD.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Hypertension. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Hypertension and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Hypertension?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Steven Coca, Associate Professor, Medicine, Nephrology; Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, Mount Sinai Health System, and Co-Founder of RenalytixAI – a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Dr. Coca is a former graduate from University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in CT. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. He was on faculty in the Section of Nephrology for 5 years as an Assistant Professor. Currently, he is an Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. His major research areas include using newer biomarkers to aide risk-stratification for outcomes in acute kidney injury and chronic kidney disease. His major clinical interests include AKI, CKD, electrolyte disorders, hypertension, and cardiorenal syndrome.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
